GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.29 USD | -0.90% |
|
-0.53% | -16.94% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.35% | 36 M€ | +3.18% | - | |
| 0.35% | 322 M€ | +13.88% | - | |
| 0.35% | 29 M€ | -.--% | - | |
| 0.34% | 1,848 M€ | +18.39% | - | |
| 0.34% | 559 M€ | +14.30% | ||
| 0.34% | 6 M€ | +17.98% | - | |
| 0.33% | 121 M€ | +8.66% | - | |
| 0.32% | 17 M€ | +5.38% | - | |
| 0.32% | 26 M€ | +22.69% | - | |
| 0.29% | 744 M€ | +9.79% | ||
| 0.29% | 8 M€ | +7.19% | - | |
| 0.28% | 37 M€ | -.--% | ||
| 0.27% | 1 M€ | -.--% | ||
| 0.26% | 7 M€ | +0.11% | - | |
| 0.25% | 50 M€ | +11.42% | ||
| 0.25% | 264 M€ | -.--% | - | |
| 0.25% | 187 M€ | +11.10% | - | |
| 0.25% | 34 M€ | +13.06% | - | |
| 0.25% | 477 M€ | +12.95% | ||
| 0.25% | 205 M€ | -.--% | ||
| 0.24% | 20 M€ | +1.13% | - | |
| 0.23% | 57 M€ | +22.83% | - | |
| 0.21% | 35 M€ | +9.64% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29
USD
Average target price
82.93
USD
Spread / Average Target
+23.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.94% | 83.83B | |
| +37.78% | 723B | |
| +31.21% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.32% | 244B | |
| -4.54% | 208B | |
| +9.86% | 210B | |
| +9.32% | 169B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.
